Top Page
Adaptimmune Therapeutics
(NASDAQ:ADAP)
Adaptimmune Therapeutics (ADAP) vs. SPDR S&P 500 ETF (SPY)
Adaptimmune Therapeutics Business Overview & Revenue Model
Adaptimmune Therapeutics Earnings Call Summary
Adaptimmune Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 65.08M | 178.03M | 60.28M | 27.15M | 6.15M | 3.96M |
| Gross Profit | 61.70M | 177.96M | 50.42M | -100.58M | -104.94M | -87.61M |
| EBITDA | -149.75M | -52.66M | -128.20M | -155.59M | -155.68M | -125.81M |
| Net Income | -169.76M | -70.81M | -113.87M | -165.46M | -158.09M | -130.09M |
Balance Sheet | ||||||
| Total Assets | 130.63M | 245.96M | 282.62M | 328.92M | 469.55M | 451.14M |
| Cash, Cash Equivalents and Short-Term Investments | 26.06M | 151.60M | 146.94M | 204.60M | 369.58M | 368.22M |
| Total Debt | 48.68M | 74.21M | 25.23M | 23.08M | 25.47M | 23.71M |
| Total Liabilities | 201.59M | 234.11M | 243.10M | 247.04M | 263.58M | 109.92M |
| Stockholders Equity | -70.96M | 11.85M | 39.51M | 81.88M | 205.96M | 341.23M |
Cash Flow | ||||||
| Free Cash Flow | -191.71M | -75.93M | -145.76M | -171.51M | 1.95M | -56.50M |
| Operating Cash Flow | -190.03M | -73.21M | -140.88M | -141.77M | 10.73M | -53.59M |
| Investing Cash Flow | 1.79M | -58.95M | 176.54M | 89.14M | 75.80M | -278.92M |
| Financing Cash Flow | 1.34M | 78.75M | 880.00K | 12.87M | 3.29M | 340.05M |
Adaptimmune Therapeutics Technical Analysis
Adaptimmune Therapeutics Risk Analysis
Adaptimmune Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
45 Neutral | $92.38M | -3.05 | -66.16% | ― | -87.65% | 11.76% | |
42 Neutral | $21.15M | -0.74 | 88.41% | ― | -44.63% | 26.79% | |
41 Neutral | $38.96M | ― | -1341.37% | ― | -53.61% | -93.14% | |
39 Underperform | $215.86M | -0.87 | ― | ― | ― | -41.69% | |
37 Underperform | $81.63M | -2.30 | ― | ― | ― | 62.83% | |
35 Underperform | $68.97M | -0.41 | ― | ― | ― | -17.96% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Adaptimmune Therapeutics Corporate Events
On September 11, 2025, Adaptimmune Therapeutics received a notice from Nasdaq indicating that its market value of listed securities had fallen below the $35 million minimum required for continued listing. The company has until March 10, 2026, to regain compliance, failing which its securities may be delisted from Nasdaq. The notice does not immediately affect the trading of its American Depositary Shares, but the company is exploring options to meet the compliance requirements.
The most recent analyst rating on (ADAP) stock is a Sell with a $0.46 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.
On September 6, 2025, Adaptimmune Limited appointed Christopher Hill as Chief Financial Officer, effective September 10, 2025. Hill, with over a decade of experience in financial roles within life science companies, will manage the company’s accounting and finance functions as an independent contractor through a consulting agreement with CJH Financial Limited. This strategic appointment highlights Adaptimmune’s focus on strengthening its financial leadership as it continues to develop its therapeutic offerings.
The most recent analyst rating on (ADAP) stock is a Sell with a $0.46 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.
Adaptimmune Therapeutics announced changes in its executive team due to redundancy, affecting Gavin Wood, the Chief Financial Officer, and John Lunger, the Chief Patient Supply Officer. Mr. Wood’s employment will end on September 9, 2025, with a severance package including a year’s salary and other benefits, while Mr. Lunger’s termination is effective August 31, 2025, with similar severance terms. These changes reflect the company’s ongoing restructuring efforts, impacting its operational dynamics and potentially influencing stakeholder relations.
The most recent analyst rating on (ADAP) stock is a Sell with a $0.46 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.
On August 15, 2025, Adaptimmune announced a separation agreement with Cintia Piccina, whose role as Chief Commercial Officer was terminated due to redundancy on August 8, 2025. As part of the agreement, Piccina will receive a severance payment equivalent to 12 months of her 2025 base salary, amounting to $473,800, and will have until January 30, 2032, to exercise her vested share options.
The most recent analyst rating on (ADAP) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.
Adaptimmune Therapeutics plc, a company involved in the biotechnology industry, faced compliance issues with Nasdaq’s listing rules due to its American Depositary Shares trading below the required minimum bid price. On November 1, 2024, the company was notified of non-compliance and given until April 30, 2025, to resolve the issue. Despite an extension granted on May 1, 2025, to October 27, 2025, the company’s shares continued to fall, prompting Nasdaq to issue a delisting notice on August 14, 2025. Adaptimmune intends to request a hearing to present its compliance plan and seek additional time to meet the listing requirements, with its shares remaining on the Nasdaq Capital Market under the symbol ‘ADAP’ during the process.
The most recent analyst rating on (ADAP) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.